Related Experiment Video
Updated: Jul 24, 2026
05:49
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
Deficient thromboxane synthesis and response in platelets from premature infants
S J Israels1, F S Odaibo, C Robertson
1Departments of Pediatrics, Manitoba Institute of Cell Biology, University of Manitaba, Winnipeg, Canada.
Pediatric Research
|February 1, 1997
Summary
Platelets from premature infants show reduced function, including impaired aggregation and serotonin secretion. This poor response is linked to deficient thromboxane A2 production, not receptor issues.
Area of Science:
- Neonatal physiology
- Platelet biology
- Cardiovascular research
Background:
- Platelet dysfunction can increase risks in premature infants.
- Thromboxane A2 (TxA2) plays a crucial role in platelet function.
- Understanding neonatal platelet response is vital for clinical care.
Purpose of the Study:
- To compare in vitro platelet function between preterm infants, full-term infants, and adults.
- To investigate the role of thromboxane A2 (TxA2) production and receptor activity in preterm infant platelets.
- To identify potential causes of impaired platelet response in neonates.
Main Methods:
- Compared platelet aggregation and [14C]serotonin secretion in response to various agonists.
- Measured thromboxane B2 (TxB2) production via ELISA.
- Assessed TxA2 receptor expression using immunoblotting and flow cytometry.
- Determined TxA2 receptor binding characteristics with [3H]U46619 ligand binding studies.
Main Results:
- Preterm infant platelets exhibited impaired aggregation and serotonin secretion compared to adults.
- TxA2 production was significantly reduced in preterm platelets.
- No significant differences were found in TxA2 receptor number or binding affinity across groups.
- Platelet response deficits are not due to altered TxA2 receptor characteristics.
Conclusions:
- Platelets from preterm infants demonstrate impaired thromboxane A2 (TxA2) production and response.
- The observed platelet dysfunction in preterm infants is likely due to postreceptor signal transduction pathway defects.
- Further research into neonatal platelet signaling pathways is warranted.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.